BOSTON, March 29, 2023 /PRNewswire/ -- Wren announced today the presentation of preclinical data for its first-in-class, oral inhibitors of α-synuclein oligomer generation demonstrating potent ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results